Latest Obesity Care Continuum Stories

WASHINGTON, July 17, 2012 /PRNewswire-USNewswire/ -- Today, members of the Obesity Care Continuum (OCC) commended the Food and Drug Administration (FDA) for their continued proactive approach to ensuring safe obesity treatment options for the more than 93 million Americans affected by the disease. (Logo: http://photos.prnewswire.com/prnh/20120531/DC16753LOGO ) "By approving another medication that will help healthcare professionals treat this disease more effectively, the FDA...

WASHINGTON, June 27, 2012 /PRNewswire-USNewswire/ -- Today, members of the Obesity Care Continuum (OCC) applauded the Food and Drug Administration's (FDA) approval of a new obesity drug - Belviq (lorcaserin HCl). Belviq is the first obesity drug to be approved in the past 13 years. "This is a tremendous step forward in addressing our most pressing health problem. Healthcare professionals now have a new option to help their patients affected by obesity manage this chronic condition....

WASHINGTON, Feb. 23, 2012 /PRNewswire-USNewswire/ -- Members of the Obesity Care Continuum (OCC) are pleased with the FDA's Advisory Committee near unanimous vote to approve QNEXA, a new drug to treat those affected by obesity and obesity-related co-morbidities, such as Type 2 diabetes, hypertension and more. "The robust discussion by the panel surrounding both the risks and benefits of new obesity drugs is both refreshing and powerful," said Obesity Action Coalition (OAC)...